Product Highlight - QDENGA

Indicated for the prevention of dengue disease caused by any dengue virus serotype in individuals from 4 years of age.¹

Protection against dengue¹

• 80.2% overall vaccine efficacy (VE) from 30 days after the second dose until the end of the 12-month follow-up after the second dose (95% CI: 73.3, 85.3) (primary endpoint) regardless of baseline serostatus¹

• 90.4% overall efficacy in preventing hospitalized dengue due to virologically confirmed dengue (VCD) fever from 30 days after the second dose until the end of the 18-month follow-up after the second dose (95% CI: 82.6, 94.7) (key secondary endpoint)¹

Long term protection (exploratory analysis)¹

• 61.2% overall VE against VCD up to 4.5 years after the second dose (95% CI: 56.0, 65.8) (exploratory analysis)¹

• 84.1% overall VE against hospitalized dengue up to 4.5 years after the second dose (95% CI: 77.8, 88.6) (exploratory analysis)¹

Generally well tolerated^1,2

• No important safety risks observed up to 4.5 years following second dose^1,2

• No evidence of enhanced disease severity in seronegative patients^1,2

• No pretesting of serostatus required^1,2

In clinical studies, the most frequently reported reactions were injection site pain, headache, myalgia, injection site erythema, malaise, asthenia, and fever¹

References:
1. Qdenga^®, Malaysia Prescribing Information, Nov 2022.
2. Tricou V, Folschweiller N, Lloyd E, Rauscher M, Biswal S. Efficacy and safety of Takeda's tetravalent dengue vaccine candidate (TAK-003) after 4.5 years of follow-up. Takeda; 2022.

For Healthcare Professionals only
C-APROM/MY/QDE/0047 Apr 2024